A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis.
Phase of Trial: Phase III
Latest Information Update: 09 Mar 2016
At a glance
- Drugs Dexlansoprazole (Primary)
- Indications Erosive oesophagitis
- Focus Therapeutic Use
- Sponsors TAP Pharmaceutical Products
- 01 Nov 2009 Primary endpoint 'Disease recurrence rate' has been met.
- 01 Nov 2009 Results have been reported in Alimentary Pharmacology and Therapeutics.
- 01 Sep 2009 Actual patient number (451) added as reported by ClinicalTrials.gov.